Evidence map›Paper›PMID 42016922›Full record

ArticleEClinicalMedicine2026

Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study.

Megan A Waldrop, Roberto Bernardo Escudero, Lina Yang, Rebekah A Camarata, Emily C Branic, Lesa Mehl, Andreja Ilić, Anne M Connolly

Registry-linked trialAbstract read
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02122952 (Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02122952 phase1completednot on this map

Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101

TypeinterventionalSponsorNovartis Gene TherapiesRan2014 to 2017Enrolled15ConditionsSpinal Muscular Atrophy 1ArmsAVXS-101
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Spinal muscular atrophy: Biology, pathogenesis, and therapeutic advances.Therapeutic advances in neurological disorders · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Megan A WaldropCenter for Gene Therapy, Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA.
Roberto Bernardo EscuderoNovartis Pharmaceuticals, One Health Plaza, East Hanover, NJ, 07936, USA.
Lina YangNovartis Pharmaceuticals, One Health Plaza, East Hanover, NJ, 07936, USA.
Rebekah A CamarataNationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA.
Emily C BranicNationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA.
Lesa MehlNovartis Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Andreja IlićNovartis Pharmaceuticals, Forum 1, Novartis Campus, CH-4056, Basel, Switzerland.
Anne M ConnollyCenter for Gene Therapy, Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: LT-001 evaluated long-term safety/efficacy of onasemnogene abeparvovec (OA) for spinal muscular atrophy (SMA) patients from START (N = 15; NCT02122952). Methods: Reported is an interim analysis (5-year totalling up to 10-years post-dose) of long-term follow-up data from START (phase 1, open-label, single-arm, dose-escalation; 2-year follow-up [Nationwide Children's Hospital, Columbus, Ohio] [first patient dosed: May 5, 2014]). Patients (symptomatic SMA type 1, biallelic Findings: The LT-001 study was initiated on September 21, 2017, and the last patient was enrolled on September 17, 2018. As of July 1, 2024, 13 START patients enrolled in LT-001 (n = 3/13, low-dose; n = 10/13, therapeutic-dose). Mean (SD); min-max age at dosing was 6·3 (0·7); 5·8-7·1 months (low-dose) and 2·8 (1·5); 0·9-5·6 months (therapeutic-dose). Mean (SD); min-max follow-up duration was 9·9 (0·2); 9·8-10·1 years (low-dose) and 8·3 (1·1); 6·8-9·6 years (therapeutic-dose). Most patients (≥70%) received nusinersen/risdiplam post-dosing. Serious adverse events (n = 11/13; 85%) were most frequently acute respiratory failure, dehydration, and pneumonia (none led to study discontinuation or death). Six adverse events (AEs) of special interest (n = 4/13; 31%) included transient thrombocytopenia, cardiac AEs, and new incidence of neurologic disorders (unrelated to treatment). All (n = 13/13) were alive at last visit (n = 5 therapeutic-dose) or data cutoff (n = 8 ongoing). The majority (n = 12/13) were free of permanent ventilation. Interpretation: OA demonstrated a favourable benefit-risk profile and efficacy up to 10 years for START/LT-001 patients, though there are limitations (descriptive analyses, small population, add-on therapy, lack of comparator). Further long-term research may build on phase 3/4 study findings with OA for SMA patients. Funding: Novartis Pharma AG.

Indexed as

Gene therapyLong-term follow-upNeuromuscular diseaseOnasemnogene abeparvovecSpinal muscular atrophy

Identifiers

PMID42016922
PMCPMC13092748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.